MD HB1087

Prohibits health insurers, nonprofit health service plans, and HMOs from imposing step therapy or fail-first protocols on FDA-approved prescription drugs used to treat stage four advanced metastatic cancer

Expands existing protections to also cover drugs prescribed by a treating physician for symptoms or side effects of stage four advanced metastatic cancer treatment

Requires that covered drugs be consistent with FDA-approved indications, National Comprehensive Cancer Network Compendium guidance, or best practices for cancer treatment, and be supported by peer-reviewed medical literature

Applies to insurers that provide prescription drug coverage through pharmacy benefits managers

Takes effect January 1, 2026, applying to all policies, contracts, and health benefit plans issued, delivered, or renewed on or after that date